406 related articles for article (PubMed ID: 12091789)
1. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
2. [Factors related to treatment adherence in schizophrenic patients].
García Cabeza I; Sánchez Díaz EI; Sanz Amador M; Gutiérrez Rodríguez M; González de Chávez M
Actas Esp Psiquiatr; 1999; 27(4):211-6. PubMed ID: 10469940
[TBL] [Abstract][Full Text] [Related]
3. [Compliance problems in treatment of schizophrenic patients].
Barnas C; Hummer M; Fleischhacker WW
Wien Med Wochenschr; 1998; 148(11-12):281-3. PubMed ID: 9746971
[TBL] [Abstract][Full Text] [Related]
4. Facilitating compliance with antipsychotic medication.
Marder SR
J Clin Psychiatry; 1998; 59 Suppl 3():21-5. PubMed ID: 9541334
[TBL] [Abstract][Full Text] [Related]
5. [Which factors modify drug-compliance?].
Albus M; Burkes S; Scherer J
Psychiatr Prax; 1995 Nov; 22(6):228-30. PubMed ID: 8570752
[TBL] [Abstract][Full Text] [Related]
6. [Adherence to neuroleptic treatment of schizophrenic patients].
Blondiaux I; Alagille M; Ginestet D
Encephale; 1988; 14(6):431-8. PubMed ID: 2906607
[TBL] [Abstract][Full Text] [Related]
7. Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects.
Young JL; Spitz RT; Hillbrand M; Daneri G
J Am Acad Psychiatry Law; 1999; 27(3):426-44. PubMed ID: 10509942
[TBL] [Abstract][Full Text] [Related]
8. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
9. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
Naber D
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
Krausz M; Sorgenfrei T
Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
[TBL] [Abstract][Full Text] [Related]
11. [Patient education about neuroleptic treatment, can it reduce costs? A pilot study].
Favrod J; Huguelet P; Chambon O
Encephale; 1996; 22(5):331-6. PubMed ID: 9035989
[TBL] [Abstract][Full Text] [Related]
12. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs.
Gaebel W
Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S37-42. PubMed ID: 9179642
[TBL] [Abstract][Full Text] [Related]
13. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
Hornung WP; Buchkremer G; Redbrake M; Klingberg S
Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
[TBL] [Abstract][Full Text] [Related]
14. Medication noncompliance in schizophrenia: codification and update.
Young JL; Zonana HV; Shepler L
Bull Am Acad Psychiatry Law; 1986; 14(2):105-22. PubMed ID: 2873851
[TBL] [Abstract][Full Text] [Related]
15. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
Hornung WP; Schonauer K; Feldmann R; Mönking HS
Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
Krausz M; Sorgenfrei T
Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
[TBL] [Abstract][Full Text] [Related]
17. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
[TBL] [Abstract][Full Text] [Related]
18. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders.
Duncan JC; Rogers R
J Forensic Sci; 1998 Nov; 43(6):1133-7. PubMed ID: 9846389
[TBL] [Abstract][Full Text] [Related]
19. Drugs and the quality of life: the patient's point of view.
Diamond R
J Clin Psychiatry; 1985 May; 46(5 Pt 2):29-35. PubMed ID: 2859278
[TBL] [Abstract][Full Text] [Related]
20. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses.
Thompson K; Kulkarni J; Sergejew AA
Schizophr Res; 2000 May; 42(3):241-7. PubMed ID: 10785582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
